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Abstract
Background: The development of new ultrasound contrast agents (UCAs) has become one of the
most promising fields in ultrasound medicine. This paper evaluates a new self-made contrast agent
enhancement effect developed to study the fibrotic stages of the liver in perfusion models in vivo.
Methods: We constructed experimental models of hepatic fibrosis involving five stages from F0
to F4 via administration of CCL4 (0.01 ml/kg BW) every 3 days for 3 months. The intrahepatic
circulatory time of the contrast agent was analyzed via an image and Cine-loop display. Calculations
of the perfusion-related parameters including the peak signal intensity (PSI) and peak signal intensity
time (PIT) of the portal vein and parenchyma were obtained from an analysis of the time-acoustic
intensity curve.
Results: Hepatic artery to vein transmit time (HA-HVTT) was significantly shorter at F4 stage
(mean 5.1 seconds) compared with those in other stages (mean 8.3 s, 7.5 s, 6.9 s, 6.6 s, P < 0.01).
The average PSI difference of PV-parenchyma was 13.62 dB in F4 stage, demonstrating significant
differences between F4 stage and other early stages (P < 0.001).
Conclusion: These results indicate that the new self-made contrast agent is capable of indicating
intrahepatic hemodynamic changes. HA-HVTT and the PSI difference of the microbubble perfusion
in liver parenchyma and PV were considered to differentiate the degree of hepatic fibrosis between
F4 and other early stages.
Background
In the 1990s, with the introduction of the microbubbles,
clinical and research applications for ultrasound were rev-
olutionized. Microbubbles consist of a gas (air or per-
fluorocarbon) stabilized by a shell (denatured albumin,
phospholipid, or surfactant or cyanoacrylate). Microbub-
bles are less than 10 µm in diameter so they can be intra-
venously injected to cross the lung bed producing a
systemic enhancement. Special imaging software and the
development of contrast microbubbles resulted in a rapid
expansion of the use of microbubbles in ultrasound scan-
ning. Microbubbles can be used as tracers and this has
Published: 8 August 2007
BMC Gastroenterology 2007, 7:32 doi:10.1186/1471-230X-7-32
Received: 22 August 2006
Accepted: 8 August 2007
This article is available from: http://www.biomedcentral.com/1471-230X/7/32
© 2007 Zhang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Gastroenterology 2007, 7:32 http://www.biomedcentral.com/1471-230X/7/32
Page 2 of 7
(page number not for citation purposes)
been exploited in liver scans to identify conditions charac-
terised by arterio-venous shunting such as cirrhosis [1,2]
and metastases [3,4] – where an early hepatic vein transit
time indicates a haemodynamic abnormality. This
approach parallels that of dynamic CT or MRI but ultra-
sound has the advantages of high spatial and temporal
resolution.
Different contrast agents have different perfusion charac-
teristics based on their components. In Lim AK's study,
SonoVue and Levovist were compared in the circulation
time. Results showed HVTT was significantly shorter with
SonoVue than with Levovist; there was no significant dif-
ference in cardiopulmonary transit time. In Prof. Gao's
earlier study, a new self-made lipid-coated contrast agent
was used in healthy rabbits. The results proved that this
new contrast agent is safe and has good perfusion charac-
teristics in hepatic parenchyma and renal cortex at a min-
imal dose of 0.01 mL/kg body weight (BW). While the
circulatory time and grey scale intensity of the microbub-
ble in liver were not systematically studied.
Liver fibrosis has been shown to be a bidirectional process
and a growing body of data from laboratory and clinical
studies show that even advanced fibrosis and cirrhosis are
potentially reversible [5]. Therefore, the need for an early
and accurate diagnostic test for liver fibrosis is essential.
Although liver biopsy is generally considered as the "gold
standard" in grading liver fibrosis, the major limitations
of liver biopsy and the absence of a suitable laboratory
screening test for liver disease in clinical practice have
resulted in the evaluation of imaging techniques for the
detection of liver disease. In a recent study, the diagnostic
accuracy of ultrasonography for cirrhosis was found to be
80% with discriminant analysis [6].
In order to further validate the safety and effectiveness of
this new contrast agent in diffused liver disease, the liver
fibrosis models were established in rabbits and the new
self-made contrast agent applied and analyzed in this
study.
Methods
Animal model
Twelve male New Zealand White rabbits weighing
between 2.0 and 2.2 kg with healthy livers were used as
subjects. The CCL4  was injected intra-abdominally in
doses of 0.10 ml/kg BW every 3 days for 3 months. This
regimen proved sufficient to produce an advanced stage of
liver fibrosis. Rabbits were taken biopsied at 30, 40, 60
and 90 days from the commencement of the CCL4 injec-
tion. The samples extracted from the liver biopsy were
fixed for histopathology.
After at least a 4 hours fast, the rabbits were anesthetized
with "Xu Mian Xin" (Changchun Argo-Pastoral Univer-
sity, Jilin, China), at a dose of 1.5 mg/kg BW by IM injec-
tion. After the abdominal skin was shaved with an 8%
Na2S solutions, the rabbits were placed in a supine posi-
tion. Additionally, prior to the contrast agent examina-
tion, an ear vein passage was established.
Staging of liver fibrosis
Representative blocks from each biopsied liver were
embedded by routine paraffin-wax processing and serially
sectioned at 5 um thickness. Afterwards, they were stained
with routine dyes (hematoxylin and eosin) and Massion's
trichrome for histopathological evaluation. These slides
were used for determining the stages of fibrosis by a
pathologist, using the five-point METAVIR scoring system
(F0-F4) [7]. This scoring system is defined as follows: F0,
no fibrosis; F1, portal fibrosis without septa; F2, portal
fibrosis with rare septa; F3, numerous septa without cir-
rhosis; and F4, cirrhosis.
Ultrasonographic examination
In order to minimize or avoid the effect of liver trauma
brought on by the biopsy, the ultrasound examinations
were delayed by two days after the pathological changes
were verified by biopsy. All subjects were tested after at
least a four hour fast. Harmonic studies were all per-
formed with a ViVid 7 (Logic, America) using a 10 MHz
probe. All examinations were performed with rabbits in
the supine position. Both the depth of field and focal zone
were kept constant during the examination. The right lobe
of lthe iver containing the right portal vein, right hepatic
vein and right hepatic artery were simultaneously scanned
in a transverse section.
The new self-made contrast agent used in this study was
generously presented by the Third Military Medical Uni-
versity. The exact ingredients of the contrast agent used in
this article include liposome, consisting of two kinds of
phospholipids and polyethylene glycol; certain media
including glucose and de-ionized water; perfluoropro-
pane, which were introduced into the suspension during
sonication. The bubbles concentration was 7 × 109/ml
and the size distribution was between 2 to 10 µm. Approx-
imately 90% of the microbubbles were less than 8 µm.
The surface electric potential was -71.2 mV and the pH
was 6.42. The manufacture procedure performed as previ-
ously described [8].
The self-made contrast agent (0.01 mL/kg BW), was
applied in a randomized order into a marginal ear vein as
a bolus followed by a 5 ml saline flush. Mechanical index
(MI) was deceased to 0.24, an experimental value verified
by Professor Gao et al. Scanning setting was for optimal
visualization, with the gain, scanning depth, field of viewBMC Gastroenterology 2007, 7:32 http://www.biomedcentral.com/1471-230X/7/32
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and time gain control (TGC), were determined through-
out the study. After these conditions were determined, the
transducer was held in a fixed position during examina-
tion. Bubble perfusion images were obtained by Cine-
loop. The delay between the time of first bubble appear-
ance in the hepatic artery, portal vein and hepatic vein was
defined as the arrival time for corresponding vessels. HA-
HVTT was defined as the time interval from the arrival
time of HA to the arrival time of HV. The time-acoustic
intensity curve was analyzed automatically by the quanti-
tative analysis software package carried by ViVid 7 after
contrast enhancement ultrasound. PV- parenchyma PIT
was defined as the time interval from the peak signal
intensity of PV to the peak signal intensity of parenchyma,
measured from the time-acoustic intensity curve. PV-
parenchyma PSI was assessed by the time-acoustic inten-
sity curve. All ultrasound examinations and data analyses
were performed by investigators blinded to the patholog-
ical changes of liver.
Statistical analysis
Data were expressed as Mean ± Standard deviation. The
analysis of variance was performed by GLM-ANOVA and
subsequent pairwise comparisons were assessed with
Tukey's procedure accounting for both animal factor and
stage factor and the fact that some animals contribute to
only a few stages. Statistical significance was defined as P
< 0.01.
Results
None of the rabbits in the 30-day treatment group died.
Among the 40-day group, 3 rabbits died and by the 60th
day, the death rate was 33% and by late on the 90th day,
half of the animals had died from gastroenteric haemor-
rhagic necrosis to CCL4 and haemorrhage from the liver
biopsy. None of the rabbits died from the administration
of the contrast agent. According to the METAVIR scoring
system, we had established 12 F0 and F1 stage models; 9
F2 stage models; 8 F3 stage models and 6 F4 stage models
(Fig 1).
The circulatory times are summarized in Table 1. At 4 s
after the bolus injection of the self-made contrast agent,
the first microbubble appeared in hepatic artery and
enhanced quickly (Fig. 2a), then the first microbubble
arrived at the portal vein at 6 s after injection (Fig. 2b).
HAAT, PVAT were not significantly different among five
stages with the mean value of 4 s and 6 s respectively.
HVAT varied at different stage. As shown in Fig. 3a, HVAT
decreased gradually from F0 stage to F4 stage, but compar-
ison between F4 and F3 stage showed no significant differ-
ence, neither did the comparison between F3 and F2
stage, F2 and F1 stage, F2 and F0 stage, F1 and F0 stage. A
parallel reduction was obtained in HA-HVTT as shown in
Fig. 3b, only in F4 stage in the rabbit liver HA-HVTT with
a mean of 5.16 s differed significantly from other four
stages (P < 0.01). Comparison between each set of two
groups from F0 to F3 stage demonstrated no statistical dif-
ferences for HA-HVTT. Results are listed in Table 2 show-
ing that HA-HVTT is able to discriminate F4 stage and
other early fibrotic stages.
Time-acoustic intensity curves indicated the changes of
intensity in the portal vein and liver parenchyma as the
time period processed. Analysis of the profile of the time
acoustic-intensity curve, showed a rapid-rising slope from
the time of the bolus injection to the PSI and a gradual-
descending slope after reaching PSI in both the portal vein
and liver parenchyma as shown in Fig. 4. PIT measured
was seen to be a little earlier in the portal vein than that in
the parenchyma in every stage. Significant differences did
not occur with PV-parenchyma PIT in the five stages. Fig.
5 showed the mean PSI parameters estimated for each
stage. PSI of PV in F4 stage was -27.46 ± 0.22 dB, very sim-
ilar to those in other stages (F0, -26.75 ± 1.09 dB; F1, -
27.45 ± 0.35 dB; F2, -27.88 ± 1.35 dB; F3, -28.89 ± 2.73
dB; P > 0.01), while PSI of parenchyma decreased with the
Illustration of the examination process Figure 2
Illustration of the examination process. (a) 4 s after a bolus 
injection of the self-made contrast agent. First, the contrast 
agent arrived at the hepatic artery (arrow) 4 s after the injec-
tion. PV was only slightly enhanced. (b) 6 s after a bolus injec-
tion of the self-made contrast agent. The contrast agent then 
arrived at both the HA and PV (arrow).
Histological changes in F2, F3 and F4 stage (× 200) using Mas- sion's trichrome stain Figure 1
Histological changes in F2, F3 and F4 stage (× 200) using Mas-
sion's trichrome stain. (a) Increasing degeneration of liver 
cells, some fatty change of liver cells were observed in F2 
stage; (b) Widespread changes in fatty cells and some fiber 
lesions (blue stained) in F3 stage; (c) Pseudo-lobule evident in 
F4 stage.BMC Gastroenterology 2007, 7:32 http://www.biomedcentral.com/1471-230X/7/32
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development of liver fibrosis. Parenchyma PSI both in F4
stage and F3 stage were clearly distinguishable from other
four stages (P < 0.01). In F1 stage, the change of paren-
chyma PSI was incapable of indicating the difference from
F0 stage and F2 stage. Interestingly, statistical analysis
demonstrated that the PSI difference in PV and liver
parenchyma between F4 stage and other four stages had
statistical significance (P < 0.001). The statistical results of
PSI difference by inter-group significance of paired com-
parison was not obtained among the F0, F1, F2 and F3
groups. Table 3 and Table 4 showed the results of PSI indi-
cating PSI difference in PV and parenchyma is the indica-
tive parameter.
Discussion
In this study, we have shown that at low MI harmonic
real-time imaging, the new self-made contrast agent
exhibited strong stability in the enhancement of hepatic
parenchyma among different fibrotic stages of rabbit liver.
Using real-time low-MI mode, the time-intensity curve
could be obtained more accurately because bubbles are
better preserved. As previously demonstrated, the per-
fusion course of contrast agents has the following proper-
ties: a parenchyma enhancement phase in the liver
parenchyma following the enhancement of the blood
pool and lasting for a relatively longer period, (also called
late-phase). Our results showed that the self-made con-
trast agent reaches the hepatic artery 4 s after administra-
tion, and reaches the portal vein 2 s later. As noted in the
previous study, grey scale enhancement could last more
than 50 min from both visual assessment and quantitative
statistical analysis [8]. In this study, we observed the
parenchyma enhancement only for the first 5 minutes to
assess peak signal intensity instead of the whole paren-
Table 1: Circulatory time of the contrast agent in animal model at different stages a
Liver fibrosis stage HAAT PVAT HVAT HA-HVVT PIT
F0 3.78 ± 0.53 5.81 ± 0.16 12.54 ± 1.21 8.68 ± 1.13 1.13 ± 0.12
F1 4.28 ± 0.16 6.48 ± 0.22 11.59 ± 1.21 7.31 ± 1.17 0.94 ± 0.13
F2 4.40 ± 0.33 7.22 ± 0.32 11.33 ± 0.88 6.90 ± 0.64 1.47 ± 0.11
F3 3.39 ± 0.42 6.91 ± 0.44 9.90 ± 1.13 6.49 ± 0.86 0.82 ± 0.42
F4 3.58 ± 0.58 6.63 ± 0.43 8.74 ± 0.61 5.16 ± 0.85 1.16 ± 0.26
aValues are Mean ± SD
HVAT and HA-HVTT comparisons among all experimental animals at different stages Figure 3
HVAT and HA-HVTT comparisons among all experimental animals at different stages. The general tendency is decent with the 
development of liver fibrosis both for HVAT (a) and HA-HVTT (b).BMC Gastroenterology 2007, 7:32 http://www.biomedcentral.com/1471-230X/7/32
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chyma enhancement period. The self-made contrast agent
characteristics are demonstrated in the time acoustic-
intensity curve profile.
HAAT and PVAT are very similar among the five fibrotic
stages. With the development of fibrosis, HVAT is earlier
and HA-HVTT shortened. In F4 stage, intrahepatic shunts
reduce the transit time through the liver, since a signifi-
cant amount of blood bypasses the liver sinusoids. In
spite of the similar change tendency, HVAT is incapable to
discriminate every stage from the earlier stage. HA-HVTT
is significantly shorter than those of other early stages
with mean of 5.13 s respectively. The tendency that HA-
HVTT in liver cirrhosis is significant shorter than that in
normal supports earlier studies [9,10].
The PSI in the portal vein is higher than that in the liver
parenchyma at every assessment stage, supporting Li J's
results [11]. As the fibrosis developed, a progressive reduc-
tion of parenchyma PSI was observed in the late phase,
which is accordance with Kaneko T's studies with Levovist
[2], but did not occur with PV PSI, accordingly the gap
between PV and parenchyma PSI is increased. Statistical
analysis show us that PV-parenchyma PSI difference is
more suitable than parenchyma PSI in separating the
stages of different degrees of fibrosis, which we found,
interestingly, similar with the analysis of contrast agent
transmit time.
A clear explanation of the reduction of parenchyma
enhancement is difficult to establish. If the contrast
microbubbles simply pool in the hepatic sinusoids, the
anatomical changes of these vessels occurring in a cir-
rhotic liver, such as capillarization, could be considered as
a possible explanation for PSI in PV always being higher
than that in parenchyma and PSI in PV being less affected
by the changes caused by liver fibrosis. The mean diameter
of the microbubble is 3–5 µm, a little larger than that of
the commercially available UCAs, such as SonoVue with a
mean diameter of 2.5 µm [12], however, more than 80%
of microbubbles are less than 8 µm. It is difficult for a
larger microbubble to diffuse in hepatic sinusoids effi-
ciently, especially when liver stiffness increases.
However, the site of this type of microbubble accumula-
tion is unknown. We assumed that the hepatic enhance-
ment phase after perfusion in blood-pool may be from
uptake by the reticuloendothelial system in liver, where
Kupffer cells play an important role [13,14]. But in other
results from anatomical studies, the number of hepatic
Kupffer cells does not differ significantly in normal sub-
jects or in cirrhotic ones [15]. The observed changes could
possibly be due, at least in part, to impaired functional
capacity of the Kupffer cells. The post-vascular enhance-
ment of Levovist lasts from several minutes to 1 hour, the
new self-made contrast agent can enhance in hepatic
parenchyma more than 50 min. In recent studies, Levovist
was confirmed to be phagocytosed by Kupffer cells both
in vitro and in vivo [16]. Considering the similarity of the
long post-vascular enhancement, the reduction of paren-
chyma enhancement may due to the Kuffer cells. The exact
reasons need to be further studied.
In this study, greater emphasis was placed on HA-HVTT
and the differences in PV-parenchyma PSI, minimizing
the error brought through administration time delay, thus
making the evaluation parameters less subjective. The cir-
culatory characteristics confirmed that the new self-made
contrast agent has the potential to differentiate early liver
cirrhosis from liver fibrosis. The new self-made contrast
Table 3: PSI of the contrast agent in animal model at different stage a
Liver fibrosis stage PSI of PV PSI of parenchyma PSI difference of PV and parenchyma
F0 -26.75 ± 1.09 -32.24 ± 0.89 6.09 ± 1.54
F1 -27.45 ± 0.35 -32.71 ± 0.46 5.40 ± 0.53
F2 -27.88 ± 1.35 -33.19 ± 0.51 5.00 ± 1.36
F3 -28.89 ± 2.72 -37.34 ± 0.69 7.12 ± 1.07
F4 -27.46 ± 0.22 -41.08 ± 0.86 13.62 ± 0.80
aValues are Mean ± SD
Table 2: Turkey's T test applied to the stages F0, F1, F2, F3 and F4 for HVAT and HA-HVTT parameters
Variables Stages
F0/F1 F0/F2 F0/F3 F0/F4 F1/F2 F1/F3 F1/F4 F2/F3 F2/F4 F3/F4
HVAT n.s. n.s. <0.01 <0.01 n.s. <0.01 <0.01 n.s. <0.01 n.s.
HA-HVVT n.s. n.s. n.s. <0.01 n.s. n.s. <0.01 n.s. <0.01 <0.01
n.s.: non-significantBMC Gastroenterology 2007, 7:32 http://www.biomedcentral.com/1471-230X/7/32
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agent based on lipids provides more advantages than con-
ventional ultrasound. It can reflect liver perfusion, espe-
cially in satisfactory enhancement of the parenchyma in
vivo in the animal model. As a consequence of the ten-
dency to accumulate in the hepatic parenchyma, this con-
trast agent can also be considered to be confined to the
vessels. In other words, based on the prolonged enhance-
ment in liver parenchyma, this new contrast agent has
potential in further diagnostic and therapeutic applica-
tion by carrying tumor markers or therapeutic drugs. Fur-
ther large-scale studies are required to accurately assess
sensitivity and specificity before the new contrast agent
can be adopted for clinical practice.
Conclusion
In summary, the new self-made contrast agent is safe
when applied in liver fibrosis models in vivo. It effectively
reflects liver haemodynamic changes and can also indi-
cate early liver cirrhosis by highlighting HA-HVTT and PSI
difference between the portal vein and parenchyma. This
data is expected to be useful for further studies in ultra-
sound diagnosis of liver fibrosis using this new contrast
agent.
Abbreviations
PSI, peak signal intensity; HA-HVTT, hepatic artery to vein
transmit time; PIT, peak signal intensity time; UCAs, ultra-
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